Enfortumab vedotin
- Generic Name
- Enfortumab vedotin
- Brand Names
- Padcev
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1346452-25-2
- Unique Ingredient Identifier
- DLE8519RWM
- Background
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to bren...
- Indication
Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting. Enfortumab vedoti...
- Associated Conditions
- Locally Advanced Urothelial Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Urothelial Cancer
- Associated Therapies
- -
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04887870
- Locations
- 🇺🇸
Local Institution - 516-014-004, Columbus, Ohio, United States
🇺🇸Local Institution - 516-014-011, Albany, New York, United States
🇺🇸Local Institution - 516-014-027, Fairfax, Virginia, United States
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 32
- Registration Number
- NCT04878029
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 34
- Registration Number
- NCT04754191
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT04225117
- Locations
- 🇯🇵
Site JP81004, Nagoya, Aichi, Japan
🇯🇵Site JP81001, Kashiwa, Chiba, Japan
🇯🇵Site JP81005, Chuo-ku, Osaka, Japan
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1030
- Registration Number
- NCT04223856
- Locations
- 🇺🇸
Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇯🇵Site JP81006, Kawasaki-shi, Japan
🇨🇳Site CN86025, Hefei, China
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- Conditions
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 857
- Registration Number
- NCT03924895
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada
🇺🇸University of Chicago ( Site 0068), Chicago, Illinois, United States
🇪🇸Hospital Universitario San Carlos ( Site 0678), Madrid, Spain
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 645
- Registration Number
- NCT03869190
- Locations
- 🇪🇸
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Taiwan University Hospital, Yun-Lin Branch, Huwei Township, Taiwan
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT03606174
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 643
- Registration Number
- NCT03547973
- Locations
- 🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- Conditions
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT03474107
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇧🇪Site BE32013, Brussels, Belgium
🇧🇪Site BE32001, Gent, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.